

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	N/A	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

Sandostatin (octreotide acetate)

CG-DRUG-45

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Quantity Limit
Sandostatin (octreotide acetate)	N/A
**Sandostatin LAR Depot (octreotide acetate) 10mg, 30mg Kit	1 kit per 28 days
**Sandostatin LAR Depot (octreotide acetate) 20mg Kit	2 kits per 28 days

**Applicable Medicaid Markets – Sandostatin LAR pharmacy policy only applicable to VA and Amerigroup Medicaid only

APPROVAL CRITERIA

- I. Sandostatin, Sandostatin LAR Depot (octreotide acetate) may be approved for the treatment of acromegaly in individuals who have had an inadequate response to or cannot be treated with surgical resection, pituitary irradiation, or bromocriptine mesylate at maximally tolerated doses.
- II. Sandostatin, Sandostatin LAR Depot (octreotide acetate) may be approved for carcinoid tumors for **any** of the following indications:
 - A. Metastatic carcinoid tumors; **OR**
 - B. Carcinoid syndrome to suppress or inhibit severe diarrhea and flushing episodes associated with the disease; **OR**
 - C. Prophylactic administration prior to biopsy in an individual with a suspected functioning carcinoid tumor; **OR**
 - D. Prophylactic administration prior to induction of anesthesia in an individual with a functional carcinoid tumor; **OR**
 - E. Prophylactic administration perioperatively to a surgical procedure in an individual with a functional carcinoid tumor.

*Supplemental treatment with short-acting octreotide acetate (Sandostatin) may be approved for rapid relief of symptoms or for breakthrough symptoms in individuals taking long-acting octreotide acetate (Sandostatin LAR Depot) when **any** of the criteria are met for carcinoid tumors.
- III. Sandostatin, Sandostatin LAR Depot (octreotide acetate) may be approved for neuroendocrine tumors for **any** of the following indications:
 - A. Management of unresectable locoregional disease or distant metastasis; **OR**
 - B. As treatment of the profuse watery diarrhea associated with VIPomas; **OR**
 - C. Treatment of underlying hypergastrinemic Zollinger-Ellison syndrome; **OR**
 - D. Prophylactic treatment prior to surgery for gastrinoma; **OR**

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

*Supplemental treatment with short-acting octreotide acetate (Sandostatin) may be approved for rapid relief of symptoms or for breakthrough symptoms in individuals taking long-acting octreotide acetate (Sandostatin LAR Depot) when **any** of the criteria are met for neuroendocrine tumors.

- IV. Sandostatin, Sandostatin LAR Depot (octreotide acetate) may be approved for an individual when criteria are met for **any** of the following indications:
- A. Bleeding gastroesophageal (GE) varices when **both** of the following are met:
 - 1. GE varices are associated with liver disease; **and**
 - 2. Octreotide acetate is used in combination with endoscopic therapy (that is, band ligation or sclerotherapy) **or** alone if endoscopic therapy is not immediately available;
 - OR**
 - B. Central nervous system (CNS) meningiomas that are surgically inaccessible, recurrent, or progressive **and** the individual is not a candidate for further radiation therapy; **OR**
 - C. Chemotherapy or radiation-induced diarrhea that is unresponsive to conventional antidiarrheal medications (for example, diphenoxylate and atropine or loperamide); **OR**
 - D. Malignant bowel obstruction - to manage gastrointestinal (GI) symptoms (such as nausea, pain, or vomiting).

*Supplemental treatment with short-acting octreotide acetate (Sandostatin) may be approved for rapid relief of symptoms or for breakthrough symptoms in individuals taking long-acting octreotide acetate (Sandostatin LAR Depot) when **any** of the criteria are met for other indications.

May NOT be approved:

Requests for Sandostatin, Sandostatin LAR Depot (octreotide acetate) may **not** be approved when the criteria above are not met and for **all** other indications, including but not limited to treatment of:

- I. Chylothorax
- II. Diarrhea associated with acquired immunodeficiency syndrome (AIDS)
- III. Gastrointestinal (GI) tract conditions, such as:
 - A. Bleeding from vascular malformations (such as, angiodysplasias, angioectasias, or arteriovenous malformations)
 - B. gastroparesis
 - C. pancreatitis
 - D. prevention of postoperative complications (for example, fistulae) following pancreatic surgery
 - E. short bowel syndrome
 - F. upper GI bleeding (such as, non-variceal hemorrhage)
- IV. Graves' ophthalmopathy
- V. Hypothalamic obesity (control of hyperinsulinemia)

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

- VI. Other carcinomas (such as, adrenal gland tumors, advanced breast cancer, hepatocellular cancer, or prostate cancer)
- VII. Polycystic kidney disease

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. *Pancreas*. 2010; 39(6):753-766.

D'Amico G, Pagliaro L, Pietrosi G, Tarantino I. Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients. *Cochrane Database Syst Rev*. 2010;(3):CD002233.

Das A, Shah PS. Octreotide for the treatment of chylothorax in neonates. *Cochrane Database Syst Rev*. 2010;(9):CD006388.

Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Am J Gastroenterol*. 2007; 102(9):2086-2102.

Gotzsche PC, Hrobjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. *Cochrane Database Syst Rev*. 2008;(3):CD000193.

Gurusamy KS, Koti R, Fusai G, Davidson BR. Somatostatin analogues for pancreatic surgery. *Cochrane Database Syst Rev*. 2013;4:CD008370.

Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. *MMWR Recomm Rep*. 2009; 58(RR-4):1-207.

Katznelson L, Laws ER Jr, Melmed S, et al.; Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2014; 99(11):3933-3951.

Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. *Endocr Pract*. 2011; 17(Suppl 4):1-44.

Moggia E, Koti R, Belgaumkar AP, et al. Pharmacological interventions for acute pancreatitis. *Cochrane Database Syst Rev*. 2017;(4):CD011384.

National Comprehensive Cancer Network®. NCCN Drugs & Biologic Compendium® (electronic version). For additional information visit the NCCN website: <http://www.nccn.org>. Accessed on September 25, 2017.

NCCN Clinical Practice Guidelines in Oncology® (NCCN). © 2017 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org>. Accessed on September 25, 2017.

Central Nervous System (CNS) Cancers (Meningiomas) (V1.2017). Revised August 18, 2017.

Neuroendocrine Tumors (V3.2017). Revised June 13, 2017.

Palliative Care (V2.2017). Revised June 1, 2017.

Thymomas and Thymic Carcinomas (V2.2017). Revised June 1, 2017.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's Syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(8):2807-2831.

Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004; 15(6):966-973.

Octreotide. In: DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated August 17, 2017. Available at: <http://www.micromedexsolutions.com>. Accessed on September 25, 2017.

Octreotide Monograph. Lexicomp® Online, American Hospital Formulary Service® (AHFS®) Online, Hudson, Ohio, Lexi-Comp., Inc. Last revised August 1, 2008. Accessed on September 25, 2017.

Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004; 80(6):394-424.

Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005; 54 Suppl 4:iv1-16.

Sandostatin [Product Information], Schafftenau, Austria. Sandoz GmbH (Novartis Pharmaceuticals Corporation, East Hanover, NY, USA); February 2012. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019667s061lbl.pdf. Accessed on September 25, 2017.

Sandostatin LAR Depot [Product Information], Schafftenau, Austria. Sandoz GmbH (Novartis Pharmaceuticals Corporation, East Hanover, NY, USA); July 2016. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021008s035lbl.pdf. Accessed on September 25, 2017.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.